Vyne Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

YARROW BIOSCIENCE

11/05/2023 21:55

* Vyne Therapeutics Inc  VYNE.OQ  reported a quarterly
adjusted
loss of $1.74​​ per share for the quarter ended in March. The
mean expectation of two analysts for the quarter was for a loss
of $2.61 per share.
    * Revenue fell 44.4% to $99.00 thousand from a year ago;
analysts
expected zero. 
    * Vyne Therapeutics Inc's reported EPS for the quarter was a
loss
of $1.74​.
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Vyne Therapeutics Inc shares had risen by 94.2% this
quarter and
gained 121.5% so far this year.
    * The company reported a quarterly loss of $5.62 million.
    * Wall Street's median 12-month price target for Vyne
Therapeutics
Inc is $72.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 08:55 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -2.61          -1.74          Beat
 Dec. 31 2022      -3.24          -3.33          Missed
 Sep. 30 2022      -3.12          -2.88          Beat
 Jun. 30 2022      -3.06          -2.34          Beat